| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Product Name | Olmutinib |
|---|
| Description | Olmutinib (BI 1482694), is a third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). It inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR. It has been investigated in Phase II clinical trials in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who developed resistance to earlier generations of EGFR tyrosine kinase inhibitor therapy. MW: 486.59. Purity ≥98% by HPLC |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; BI1482694 |
|---|
| Gene, Accession, CAS # | CAS: 1353550-13-6 |
|---|
| Catalog # | B1218-5 |
|---|
| Price | |
|---|
| Order / More Info | Olmutinib from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|